Developer docs
API playgroundTry for free, no card

Search company profiles

SpyBiotech

Full company profile

uuid0000uge

Namestring
SpyBiotech
Legal namestring
SpyBiotech Limited
Websiteurl
spybiotech.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SpyBiotech is a clinical-stage biotechnology company founded in 2017 as a spin-out from the University of Oxford, headquartered in Oxford, UK with a US office in Cambridge, Massachusetts. The company develops vaccine candidates against infectious diseases and cancer using its proprietary SpyTag/SpyCatcher protein superglue technology, which enables covalent, irreversible conjugation of antigens to vaccine delivery platforms such as virus-like particles (SPYVLP platform) and adenoviral vectors (SPYVECTOR platform), providing controlled orientation and density of antigen presentation. Its lead candidate, SPYVLP01, targets human cytomegalovirus (HCMV) and completed enrollment in a 120-participant Phase I trial in the UK in July 2024; additional programs include a COVID-19 VLP vaccine partnered with the Serum Institute of India and three Epstein-Barr virus (EBV) vaccine candidates being advanced with the University of Oxford's Jenner Institute.

The company operates a hybrid business model combining proprietary clinical development with licensing and co-development partnerships. Revenue streams, to the extent they exist, derive from milestone and licensing payments under agreements such as the exclusive global license with the Serum Institute of India, sponsored research collaborations with academic institutions, and non-dilutive grant funding (notably a $4.1M Bill & Melinda Gates Foundation grant for the SpyVector program). The company does not yet sell approved products and pricing details for pipeline candidates are undisclosed. Customer segments are defined by use cases: the HCMV vaccine opportunity (estimated at over $1.0-1.5B annually) and the EBV vaccine opportunity (estimated at $1.0-1.5B for mononucleosis prevention and up to $10B for MS-linked indications), addressing high-unmet-need populations including pregnant women, transplant recipients, and immunocompromised individuals.

Short descriptiontext

SpyBiotech is a clinical-stage biotech developing vaccines against infectious diseases and cancer using its proprietary SpyTag/SpyCatcher protein superglue platform, with a lead HCMV candidate in Phase I trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine platform technology, protein superglue technology, virus-like particle vaccines, adenovirus vaccine vectors, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Vaccines and Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Development and Commercialization
TypeOne Time License
Description

SpyBiotech develops proprietary vaccine candidates targeting infectious diseases and cancer using its proprietary SPYVLP and SPYVECTOR platforms. Revenue is generated through advancement of clinical candidates toward regulatory approval and commercialization, with a focus on high-value markets such as HCMV and EBV vaccines.

spybiotech.com
2Licensing and Technology Partnerships
TypeLicensing Royalties
Description

SpyBiotech licenses its SpyTag/SpyCatcher technology to partners such as the Serum Institute of India for vaccine development. Exclusive global licensing agreements provide commercial rights while SpyBiotech retains platform technology capabilities. The company also provides technology access to academic collaborators for co-development.

spybiotech.com
3Grant Funding
TypeProfessional Services
Description

The company receives grant funding from foundations (e.g., Bill & Melinda Gates Foundation) to advance platform technology development and specific vaccine programs such as the SpyVector platform for pan-coronavirus vaccines.

spybiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SpyBiotech is a clinical-stage biotechnology company that develops vaccine candidates against infectious diseases and cancer using its proprietary SpyTag/SpyCatcher protein superglue technology. The company operates two proprietary platforms — SPYVLP (virus-like particle display) and SPYVECTOR (recombinant adenovirus) — and licenses the underlying technology to large vaccine manufacturers such as the Serum Institute of India while advancing its own internal pipeline (lead candidate SPYVLP01 targeting HCMV, plus COVID-19 and EBV programs).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • In non-human primate studies, a COVID-19 vaccine using SpyTag/SpyCatcher technology showed neutralising antibody titres (>10^4) above the range of protection provided by other licensed vaccines in pre-clinical studies.
+2 more records
Product overview1 text field

SpyBiotech is a clinical-stage biotechnology company developing vaccines using its proprietary SpyTag/SpyCatcher protein superglue technology. The company operates two main platform technologies: the SPYVLP Platform for displaying antigens on virus-like particles and the SPYVECTOR Platform for adenovirus-based vaccines. The lead product candidate is SPYVLP01 targeting human cytomegalovirus (HCMV) in Phase I trials. Additional pipeline includes COVID-19 VLP vaccines (developed with Serum Institute of India) and EBV vaccine candidates (developed with University of Oxford). The technology enables rapid, efficient, and stable antigen binding to vaccine delivery platforms with broad applicability across infectious diseases, cancer, and chronic diseases.

Product and service5 records
1SPYVLP Platform
CategoryVaccine Platform Technology
Description

Virus-like particle (VLP) vaccine platform that uses the proprietary SpyTag/SpyCatcher protein superglue to covalently and irreversibly bind antigens to licensed VLP carriers (e.g., Hepatitis B surface antigen) with controlled orientation and high density, enabling rapid, modular plug-and-display vaccine design for infectious disease and cancer applications.

2SPYVECTOR Platform
CategoryVaccine Platform Technology
Description

Recombinant adenovirus vaccine platform that enables covalent surface decoration of adenovirus vectors with pathogen antigens in addition to genetic encoding, boosting antibody response while maintaining T cell response and shielding against anti-vector immunity to allow repeated administration.

3SPYVLP01 (HCMV Vaccine Candidate)
CategoryVaccine Product Candidate
Description

Lead internal vaccine candidate targeting human cytomegalovirus (HCMV) using the SPYVLP Hepatitis B virus-like-particle platform; assessed in a UK Phase I trial for safety and immunogenicity at two doses with a six-month dosing schedule.

4COVID-19 VLP Vaccine (Serum Institute Partnership)
CategoryVaccine Product Candidate
Description

Virus-like particle vaccine targeting COVID-19, developed in partnership with the Serum Institute of India, which uses SpyTag/SpyCatcher to display the coronavirus spike protein receptor-binding domain on Hepatitis B surface antigen VLPs; the Serum Institute retains manufacturing and commercialization rights.

5EBV Vaccine Candidates (University of Oxford Collaboration)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-23
Description

SpyBiotech entered a sponsored research agreement with the University of Oxford for EBV vaccine development. Professor Sandy Douglas and his team at the Jenner Institute will advance three EBV vaccine candidates using SpyBiotech's SPYVLP platform through Phase I clinical trials. The collaboration combines Oxford's academic research capabilities with SpyBiotech's proprietary technology platform. SpyBiotech provides platform access and receives pre-clinical and clinical data from the collaboration.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-04-29
Description

Multi-institutional collaboration including Massachusetts Institute of Technology, University of Kansas, Bioreliance, and Beth Israel Deaconess, along with the Bill & Melinda Gates Foundation, contributed to research published in Science Advances demonstrating SpyTag/SpyCatcher vaccine platform potential against COVID-19 and other coronaviruses in non-human primates.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

Scripps Research used SpyTag/SpyCatcher technology for display of SARS-CoV-2 RBD on ferritin nanoparticles for vaccine development, demonstrating that the receptor-binding domain and stabilized spike displayed on ferritin nanoparticles elicited potent immune responses.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-09-08
Description

SpyBiotech signed an exclusive global licensing agreement with the Serum Institute of India for the development of a novel VLP vaccine targeting COVID-19. The partnership leverages SIIPL's manufacturing scale (world's largest vaccine manufacturer by doses, ~1.6 billion doses annually) and SpyBiotech's SpyTag/SpyCatcher technology to display coronavirus spike protein on Hepatitis B surface antigen VLPs. The Phase I/II trial was initiated in Australia in September 2020. SIIPL retains manufacturing and commercialization rights for the COVID-19 vaccine candidate under this agreement.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing vaccines using a chimpanzee adenovirus (ChAdOx) platform — the same viral vector backbone that powers SpyBiotech's SPYVECTOR platform. Both companies are Oxford-originated and target infectious disease and oncology indications through adenoviral delivery.

TypeDirect peer
Description

Develops recombinant nanoparticle/VLP-based vaccines (Matrix-M adjuvant + self-assembling nanoparticle antigens) — a structurally analogous approach to SpyBiotech's SPYVLP platform that displays antigens on particulate carriers to enhance immunogenicity.

TypeDirect peer
Description

Develops enveloped VLP (eVLP) vaccines targeting infectious diseases including cytomegalovirus (CMVaccine) — a direct competitor to SpyBiotech's SPYVLP01 in the same HCMV indication, using a similar VLP-display approach.

TypeDirect peer
Description

Develops conjugate and protein-based vaccines using cell-free protein synthesis to display antigens on VLP-like carriers — a platform-architecture peer to SpyBiotech's SpyTag/SpyCatcher VLP display technology, with overlapping target indications in infectious disease.

TypeDirect peer
Description

Developed the Multiple Antigen Presenting System (MAPS) for VLP-display of polysaccharide and protein antigens — a near-direct technological analog to SpyBiotech's protein superglue platform. Affinivax was acquired by GSK for up to $3.3 billion, demonstrating the strategic value of VLP-display platforms in the eyes of large vaccine players.

TypeDirect peer
Description

Develops VLP-based vaccines using computationally designed two-component particles to display antigens — a comparable platform-architecture play in infectious disease vaccines, including RSV and hMPV programs that overlap with SpyBiotech's infectious disease focus.

TypeBroad incumbent
Description

mRNA-based vaccine leader with a clinical-stage HCMV candidate (mRNA-1647) directly competing with SpyBiotech's SPYVLP01 in the same lead indication. Represents a much larger, better-capitalized incumbent pursuing the same opportunity with a different technology modality.

TypeBroad incumbent
Description

Established vaccine major with active HCMV and EBV vaccine programs (and acquirer of Affinivax). The Chairman Eddie Gray and Senior Medical Advisor Norman Begg both came from GSK, reflecting its role as both a strategic competitor and the most likely strategic acquirer of platform vaccine companies like SpyBiotech.

TypeBroad incumbent
Description

Major vaccine incumbent (Gardasil, Vaxneuvance) with a substantial infectious disease pipeline that competes in similar indications as SpyBiotech and has historical efforts in CMV vaccines. Large enough to be a potential strategic acquirer of platform vaccine technology.

TypeEmerging player
Description

Clinical-stage mRNA vaccine company with overlapping infectious disease targets (COVID-19, flu, rabies). Norman Begg, SpyBiotech's Senior Medical Advisor, also serves on CureVac's Scientific Advisory Board, reflecting an adjacent emerging-player relationship in vaccine technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SpyBiotech

Vaccines and Biopharmaceuticalsspybiotech.com

SpyBiotech is a clinical-stage biotech developing vaccines against infectious diseases and cancer using its proprietary SpyTag/SpyCatcher protein superglue platform, with a lead HCMV candidate in Phase I trials.

What SpyBiotech does

SpyBiotech is a clinical-stage biotechnology company founded in 2017 as a spin-out from the University of Oxford, headquartered in Oxford, UK with a US office in Cambridge, Massachusetts. The company develops vaccine candidates against infectious diseases and cancer using its proprietary SpyTag/SpyCatcher protein superglue technology, which enables covalent, irreversible conjugation of antigens to vaccine delivery platforms such as virus-like particles (SPYVLP platform) and adenoviral vectors (SPYVECTOR platform), providing controlled orientation and density of antigen presentation. Its lead candidate, SPYVLP01, targets human cytomegalovirus (HCMV) and completed enrollment in a 120-participant Phase I trial in the UK in July 2024; additional programs include a COVID-19 VLP vaccine partnered with the Serum Institute of India and three Epstein-Barr virus (EBV) vaccine candidates being advanced with the University of Oxford's Jenner Institute.

The company operates a hybrid business model combining proprietary clinical development with licensing and co-development partnerships. Revenue streams, to the extent they exist, derive from milestone and licensing payments under agreements such as the exclusive global license with the Serum Institute of India, sponsored research collaborations with academic institutions, and non-dilutive grant funding (notably a $4.1M Bill & Melinda Gates Foundation grant for the SpyVector program). The company does not yet sell approved products and pricing details for pipeline candidates are undisclosed. Customer segments are defined by use cases: the HCMV vaccine opportunity (estimated at over $1.0-1.5B annually) and the EBV vaccine opportunity (estimated at $1.0-1.5B for mononucleosis prevention and up to $10B for MS-linked indications), addressing high-unmet-need populations including pregnant women, transplant recipients, and immunocompromised individuals.

SpyBiotech firmographics

Firmographics
Name
SpyBiotech
Legal name
SpyBiotech Limited
Website
https://spybiotech.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
SpyBiotech is a clinical-stage biotech developing vaccines against infectious diseases and cancer using its proprietary SpyTag/SpyCatcher protein superglue platform, with a lead HCMV candidate in Phase I trials.
Ownership category
akta.pro rank

SpyBiotech industry classification

Industry
Product category
Vaccines and Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines

Keywords

  • Vaccine platform technology
  • Protein superglue technology
  • Virus-like particle vaccines
  • Adenovirus vaccine vectors
  • Clinical-stage biotechnology

Where SpyBiotech is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

SpyBiotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Vaccine Development and Commercialization: SpyBiotech develops proprietary vaccine candidates targeting infectious diseases and cancer using its proprietary SPYVLP and SPYVECTOR platforms. Revenue is generated through advancement of clinical candidates toward regulatory approval and commercialization, with a focus on high-value markets such as HCMV and EBV vaccines.
  2. Licensing and Technology Partnerships: SpyBiotech licenses its SpyTag/SpyCatcher technology to partners such as the Serum Institute of India for vaccine development. Exclusive global licensing agreements provide commercial rights while SpyBiotech retains platform technology capabilities. The company also provides technology access to academic collaborators for co-development.
  3. Grant Funding: The company receives grant funding from foundations (e.g., Bill & Melinda Gates Foundation) to advance platform technology development and specific vaccine programs such as the SpyVector platform for pan-coronavirus vaccines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

SpyBiotech product offering

Product offering

Core offering

SpyBiotech is a clinical-stage biotechnology company that develops vaccine candidates against infectious diseases and cancer using its proprietary SpyTag/SpyCatcher protein superglue technology. The company operates two proprietary platforms — SPYVLP (virus-like particle display) and SPYVECTOR (recombinant adenovirus) — and licenses the underlying technology to large vaccine manufacturers such as the Serum Institute of India while advancing its own internal pipeline (lead candidate SPYVLP01 targeting HCMV, plus COVID-19 and EBV programs).

Product overview

SpyBiotech is a clinical-stage biotechnology company developing vaccines using its proprietary SpyTag/SpyCatcher protein superglue technology. The company operates two main platform technologies: the SPYVLP Platform for displaying antigens on virus-like particles and the SPYVECTOR Platform for adenovirus-based vaccines. The lead product candidate is SPYVLP01 targeting human cytomegalovirus (HCMV) in Phase I trials. Additional pipeline includes COVID-19 VLP vaccines (developed with Serum Institute of India) and EBV vaccine candidates (developed with University of Oxford). The technology enables rapid, efficient, and stable antigen binding to vaccine delivery platforms with broad applicability across infectious diseases, cancer, and chronic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • SPYVLP Platform Virus-like particle (VLP) vaccine platform that uses the proprietary SpyTag/SpyCatcher protein superglue to covalently and irreversibly bind antigens to licensed VLP carriers (e.g., Hepatitis B surface antigen) with controlled orientation and high density, enabling rapid, modular plug-and-display vaccine design for infectious disease and cancer applications.
  • SPYVECTOR Platform Recombinant adenovirus vaccine platform that enables covalent surface decoration of adenovirus vectors with pathogen antigens in addition to genetic encoding, boosting antibody response while maintaining T cell response and shielding against anti-vector immunity to allow repeated administration.
  • SPYVLP01 (HCMV Vaccine Candidate) Lead internal vaccine candidate targeting human cytomegalovirus (HCMV) using the SPYVLP Hepatitis B virus-like-particle platform; assessed in a UK Phase I trial for safety and immunogenicity at two doses with a six-month dosing schedule.
  • COVID-19 VLP Vaccine (Serum Institute Partnership) Virus-like particle vaccine targeting COVID-19, developed in partnership with the Serum Institute of India, which uses SpyTag/SpyCatcher to display the coronavirus spike protein receptor-binding domain on Hepatitis B surface antigen VLPs; the Serum Institute retains manufacturing and commercialization rights.
  • EBV Vaccine Candidates (University of Oxford Collaboration)

Quantifiable outcome

  • In non-human primate studies, a COVID-19 vaccine using SpyTag/SpyCatcher technology showed neutralising antibody titres (>10^4) above the range of protection provided by other licensed vaccines in pre-clinical studies.
  • +2 more outcomes

Companies that use SpyBiotech

Customer profile

Segments2 records

Ideal customer profiles3 records

SpyBiotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SpyBiotech partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • University of OxfordcoreStrategic or Co-development Partner · 23 May 2024SpyBiotech entered a sponsored research agreement with the University of Oxford for EBV vaccine development. Professor Sandy Douglas and his team at the Jenner Institute will advance three EBV vaccine candidates using SpyBiotech's SPYVLP platform through Phase I clinical trials. The collaboration combines Oxford's academic research capabilities with SpyBiotech's proprietary technology platform. SpyBiotech provides platform access and receives pre-clinical and clinical data from the collaboration.
  • MIT / University of Kansas / Bioreliance / Beth Israel DeaconessminorStrategic or Co-development Partner · 29 April 2022Multi-institutional collaboration including Massachusetts Institute of Technology, University of Kansas, Bioreliance, and Beth Israel Deaconess, along with the Bill & Melinda Gates Foundation, contributed to research published in Science Advances demonstrating SpyTag/SpyCatcher vaccine platform potential against COVID-19 and other coronaviruses in non-human primates.
  • Scripps ResearchminorStrategic or Co-development Partner · 1 October 2021Scripps Research used SpyTag/SpyCatcher technology for display of SARS-CoV-2 RBD on ferritin nanoparticles for vaccine development, demonstrating that the receptor-binding domain and stabilized spike displayed on ferritin nanoparticles elicited potent immune responses.
  • Serum Institute of India (SIIPL)coreOEM/ Whitelabel/ Licensing Partner · 8 September 2020SpyBiotech signed an exclusive global licensing agreement with the Serum Institute of India for the development of a novel VLP vaccine targeting COVID-19. The partnership leverages SIIPL's manufacturing scale (world's largest vaccine manufacturer by doses, ~1.6 billion doses annually) and SpyBiotech's SpyTag/SpyCatcher technology to display coronavirus spike protein on Hepatitis B surface antigen VLPs. The Phase I/II trial was initiated in Australia in September 2020. SIIPL retains manufacturing and commercialization rights for the COVID-19 vaccine candidate under this agreement.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

SpyBiotech competitors and assessment

Company assessment

Direct peers

  • Vaccitech: Clinical-stage biotech developing vaccines using a chimpanzee adenovirus (ChAdOx) platform — the same viral vector backbone that powers SpyBiotech's SPYVECTOR platform. Both companies are Oxford-originated and target infectious disease and oncology indications through adenoviral delivery.
  • Novavax: Develops recombinant nanoparticle/VLP-based vaccines (Matrix-M adjuvant + self-assembling nanoparticle antigens) — a structurally analogous approach to SpyBiotech's SPYVLP platform that displays antigens on particulate carriers to enhance immunogenicity.
  • VBI Vaccines: Develops enveloped VLP (eVLP) vaccines targeting infectious diseases including cytomegalovirus (CMVaccine) — a direct competitor to SpyBiotech's SPYVLP01 in the same HCMV indication, using a similar VLP-display approach.
  • Vaxcyte: Develops conjugate and protein-based vaccines using cell-free protein synthesis to display antigens on VLP-like carriers — a platform-architecture peer to SpyBiotech's SpyTag/SpyCatcher VLP display technology, with overlapping target indications in infectious disease.
  • Affinivax: Developed the Multiple Antigen Presenting System (MAPS) for VLP-display of polysaccharide and protein antigens — a near-direct technological analog to SpyBiotech's protein superglue platform. Affinivax was acquired by GSK for up to $3.3 billion, demonstrating the strategic value of VLP-display platforms in the eyes of large vaccine players.
  • Icosavax: Develops VLP-based vaccines using computationally designed two-component particles to display antigens — a comparable platform-architecture play in infectious disease vaccines, including RSV and hMPV programs that overlap with SpyBiotech's infectious disease focus.

Broad incumbents

  • Moderna: mRNA-based vaccine leader with a clinical-stage HCMV candidate (mRNA-1647) directly competing with SpyBiotech's SPYVLP01 in the same lead indication. Represents a much larger, better-capitalized incumbent pursuing the same opportunity with a different technology modality.
  • GSK: Established vaccine major with active HCMV and EBV vaccine programs (and acquirer of Affinivax). The Chairman Eddie Gray and Senior Medical Advisor Norman Begg both came from GSK, reflecting its role as both a strategic competitor and the most likely strategic acquirer of platform vaccine companies like SpyBiotech.
  • Merck: Major vaccine incumbent (Gardasil, Vaxneuvance) with a substantial infectious disease pipeline that competes in similar indications as SpyBiotech and has historical efforts in CMV vaccines. Large enough to be a potential strategic acquirer of platform vaccine technology.

Emerging players

  • CureVac: Clinical-stage mRNA vaccine company with overlapping infectious disease targets (COVID-19, flu, rabies). Norman Begg, SpyBiotech's Senior Medical Advisor, also serves on CureVac's Scientific Advisory Board, reflecting an adjacent emerging-player relationship in vaccine technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

SpyBiotech social profiles

Digital presence

SpyBiotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SpyBiotech leadership team

Management profile

Number of profiles

Profiles15 records

SpyBiotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SpyBiotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpyBiotech

What does SpyBiotech do?

SpyBiotech is a clinical-stage biotechnology company that develops vaccine candidates against infectious diseases and cancer using its proprietary SpyTag/SpyCatcher protein superglue technology. The company operates two proprietary platforms — SPYVLP (virus-like particle display) and SPYVECTOR (recombinant adenovirus) — and licenses the underlying technology to large vaccine manufacturers such as the Serum Institute of India while advancing its own internal pipeline (lead candidate SPYVLP01 targeting HCMV, plus COVID-19 and EBV programs).

Is SpyBiotech a public or private company?

SpyBiotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was SpyBiotech founded?

SpyBiotech was founded in 2017. It employs 11 to 50 people.

Where is SpyBiotech based?

SpyBiotech is headquartered in Oxford, United Kingdom, in the Europe region.

How does SpyBiotech make money?

Three revenue lines are on record. Vaccine Development and Commercialization is the primary driver. The others are licensing and Technology Partnerships and grant Funding.

Who are SpyBiotech's main competitors?

Direct peers on record are Vaccitech, Novavax, VBI Vaccines, Vaxcyte, Affinivax and Icosavax. Broad incumbents are Moderna, GSK and Merck. CureVac is listed as an emerging player.

Does SpyBiotech have an API?

No public API is recorded for SpyBiotech.

What industry is SpyBiotech in?

SpyBiotech's product category is Vaccines and Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogSpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of OxfordSpyBiotech announced a sponsored research agreement with the University of Oxford to develop an Epstein-Barr virus vaccine using its SPYVLP platform. The project will advance three vaccine candidates to a Phase I clinical trial, which will be conducted through the university. The company is currently running a Phase I trial for its HCMV vaccine.BenzingaBill Gates's March Venture Investments: Biotech, Energy, And Taking On Methane EmissionsBill Gates made multiple venture investments in March across biotech and clean energy sectors through his personal portfolio and Breakthrough Energy Ventures, the investment arm of the Bill and Melinda Gates Foundation. The biotech investments include SpyBiotech (vaccine development), DelSiTech (nanoparticle drug delivery), Noze (disease-detecting digital nose technology), and Zoetis (livestock medicine and methane reduction). The energy investments through Breakthrough Energy Ventures include Stratus Materials (lithium-ion battery materials), ClearFlame Engine Technologies (ethanol fuel solutions for diesel engines), and Viridos (algae-based biofuels for aviation and maritime transport).BioSpaceSpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic VirusesSpyBiotech received a $4,094,561 grant from the Bill & Melinda Gates Foundation to further develop its SpyVector platform for creating broadly cross-protective coronavirus vaccines. The funding supports the application of the company's 'plug and display' technology to design next-generation pan-SARS-CoV-2 and pan-sarbecovirus vaccines.Labiotech.euSpyBiotech receives more than $4 million to develop vaccine platformUK-based SpyBiotech has secured a grant exceeding $4 million from the Bill & Melinda Gates Foundation to advance its SpyVector platform for developing cross-protective coronavirus vaccines. This funding supports continued research into a platform that enhances antibody production and T-cell responses while mitigating anti-vector immunity, with efficacy trials for COVID-19 candidates yet to commence. The company also plans to initiate clinical trials for a human cytomegalovirus vaccine using its Hepatitis B virus-like particle technology.PharmiWeb.comSpyBiotech Receives Grant to Advance Novel SpyVector Platform That Improves Efficacy and Boosting Capability of Adenovirus-based Vaccines Against Current and Future Pandemic VirusesSpyBiotech has received a $4,094,561 grant from the Bill & Melinda Gates Foundation to advance its SpyVector platform for developing next-generation pan-SARS-CoV-2 and pan-sarbecovirus vaccines. The funding supports the use of SpyBio’s 'plug and display' technology to design broadly cross-protective coronavirus vaccines with enhanced efficacy.BioSpaceSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive OfficerSpyBiotech appointed Mark Leuchtenberger as CEO and board member, with Sumi Biswas remaining president and CSO. The company established a US office in Cambridge, Massachusetts, and plans clinical studies for its HCMV vaccine candidate in 2023.The Pharma LetterSelexis signs license deal with SpyBiotech on HCMV vaccine programSelexis signed a commercial license agreement with UK biotech SpyBiotech to advance its lead vaccine program for human cytomegalovirus (HCMV). SpyBiotech will use Selexis' SUREtechnology Platform to generate cell lines for advancing the program to human clinical trials.UnquoteBraavos leads SpyBiotech's $32.5m series-ABraavos Investment Advisers led a $32.5m series-A round for SpyBiotech, with Oxford Investment Consultants joining and prior investors participating. The company will use proceeds to advance its vaccine technology platform's clinical development. Lutz Giebel was appointed chairman.FinSMEsSpyBiotech Raises $32.5M in Series A FundingSpyBiotech raised $32.5M in Series A funding led by Braavos Investment Advisers, with participation from Oxford Investment Consultants, Oxford Sciences Innovation, GV, and the UK Future Fund. The company will use the funds to advance its vaccine platform, planning a Phase I clinical study for its HCMV candidate in early 2022.Trust & Safety PoliciesNotch Soars Out of the Gate with $85 Million; Two More Follow Closely BehindNotch Therapeutics led a $85 million Series A, joined by SpyBiotech's $32.5 million and neoX Biotech's $30 million rounds. Notch's funding supports preclinical cancer immunotherapies, while SpyBiotech's vaccine and neoX's AI-based protein degraders are also advancing.